Methylglyoxal-modified host proteins (MG-AGEs)

Methylglyoxal (MG) is a highly reactive dicarbonyl byproduct of glycolysis that non-enzymatically reacts with the amino groups of host proteins, particularly arginine and lysine residues, to form advanced glycation end products (AGEs) (Rabbani & Thornalley, 2015, PMID: 25595318). This process, known as glycation, leads to the formation of stable adducts such as methylglyoxal-derived hydroimidazolone 1 (MG-H1) and N-epsilon-(carboxyethyl)lysine (CEL), which cause protein cross-linking and structural impairment (Schalkwijk & Stehouwer, 2020, PMID: 31915141). The accumulation of these MG-modified proteins induces oxidative stress and triggers pro-inflammatory signaling through receptors like RAGE, contributing significantly to the pathogenesis of diabetic complications, including nephropathy, retinopathy, and neuropathy (Bierhaus et al., 2005, PMID: 16151450). Furthermore, MG-AGEs are implicated in age-related conditions such as atherosclerosis and neurodegenerative diseases like Alzheimer's (Vistoli et al., 2013, PMID: 23606035). Therapeutic strategies aimed at this target include the use of MG scavengers like aminoguanidine and metformin, as well as AGE-breakers like alagebrium, which attempt to prevent or reverse the damage caused by these modifications (Thornalley, 2003, PMID: 12865317).

Other names

Methylglyoxal-derived advanced glycation end productsMG-derived AGEsGlycated host proteinsMG-H1 modified proteinsMethylglyoxal-mediated advanced glycation end products

Therapeutic agents target this process by scavenging reactive methylglyoxal precursors, inhibiting the chemical rearrangement of Amadori products into stable AGEs, or enzymatically breaking established protein-protein cross-links (Thornalley, 2003, PMID: 12865317; Vistoli et al., 2013, PMID: 23606035).